Establishment of a standard assay method for human thrombomodulin and determination of the activity of the Japanese reference standard

Biologicals

Volumn 30, Issue 1, 2002, Pages 69-76

  Niimi, Shingo ^a   Oshizawa, Tadashi ^a   Naotsuka, Masaaki ^b   Ohba, Sumiaki ^b   Yokozawa, Akira ^c   Murata, Tomoyo ^c   Hayakawa, Takao ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b MOCHIDA PHARMACEUTICAL CO   (Japan)

^c ASAHI CHEMICAL INDUSTRY CO   (Japan)

Author keywords

Activity; Reference standard; Standard method; Thrombomodulin

Indexed keywords

4 NITROANILINE; HEPARIN; PROTAC; PROTEIN C; PYROGLUTAMYLPROLYLARGININE 4 NITROANILIDE; THROMBOMODULIN; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; DOSE RESPONSE; PRIORITY JOURNAL; STANDARD; VALIDATION PROCESS;

ARRHENIUS;

EID: 0036144952     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.2001.0318     Document Type: Article

References (29)

1. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C
2. Isolation of a membrane bound cofactor for thrombin-catalyzed activation of protein C
3. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation
4. Thrombomodulin blocks the ability of thrombin to activate platelets
5. Isolation and characterization of thrombomodulin from bovine lung
6. Anticoagulant properties of bovine plasma protein C following activation by thrombin
7. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V
8. Preparation and properties of bovine factor VIII (antihemophilic factor)
9. Studies of the capacity of factor Xa to protect Factor Va from inactivation by activated protein C
10. Mechanism of action of human protein C, a thrombin dependent anticoagulant enzyme
11. Protein C: Biochemistry, physiology, and clinical implications
12. Inactivation of human coagulation factor V by activated protein C
13. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V
14. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity
15. Evidence that the protein C activation pathway amplifies the inhibition of thrombin generation by recombinant human thrombomodulin in plasma
16. The glycosaminoglycan of recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced disseminated intravascular coagulation
17. Antithrombotic effects of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats
18. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III
19. Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats
20. Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo
21. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: Comparison with low molecular weight heparin
22. The antithrombotic effects of recombinant human soluble thrombomodulin (rhs TM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis)
23. Antithrombotic effects of recombinant human soluble thrombomodulin (rhs-TM) on arteriovenous shunt thrombosis in rats
24. Intravenous recombinant soluble human thrombomodulin prevents venous thrombosis in a rat model
25. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice
26. The roles played by the D2 and D3 domains of thrombomodulin in its function
27. Fast functional protein C assay using Protac®, a novel protein C activator
28. Solid stability; Drug stability, principles and practice